Clinical Trials on C. Diff in Singapore

Total 18 results

Changi General Hospital
National University Hospital, Singapore

Completed

Epidemiology of Chronic Hepatitis C and Disease Modelling (EPIC)

Hepatitis C

Singapore
Changi General Hospital

Completed

Prevalence of IL28B Polymorphism in Hepatitis C Patients

Hepatitis C

Singapore
AbbVie

Completed

A Study of of Glecaprevir/Pibrentasvir in Adults With Chronic Hepatitis C Virus (HCV) Genotype 5 or 6 Infection (ENDURANCE-5 6)

Hepatitis C Virus (HCV)

United States, Australia, Belgium, Canada, France, New Zealand, Singapore, South Africa, Vietnam
Mina Alpha Limited

Active, not recruiting

Radomised Phase II Study of MTL-CEBPA Plus Sorafenib or Sorafenib Alone (OUTREACH2)

Hepatitis B | Hepatocellular Carcinoma | Hepatitis C

Singapore, United States
Janssen Research & Development, LLC

Terminated

A Long Term Follow-up Study in Participants Treated in a Preceding Phase 2 or 3 Study With a Regimen Containing Odalasvir and AL-335 With or Without Simeprevir for the Treatment of Hepatitis C Virus (HCV) Infection

Hepatitis C

Singapore, Canada, Poland, New Zealand
Pfizer

Terminated

Safety And Efficacy Of Oral PF-4136309 In Patients With Chronic Hepatitis C Infection And Abnormal Liver Enzymes

Hepatitis C, Chronic

Taiwan, Singapore, India, Korea, Republic of, Hong Kong
Gilead Sciences

Completed

Efficacy and Safety of Sofosbuvir/Velpatasvir Fixed Dose Combination for 12 Weeks in Participants With Chronic HCV

Hepatitis C Virus Infection

Singapore, Vietnam, China, Thailand, Malaysia
Novartis Pharmaceuticals

Terminated

Study Efficacy and Safety of INC280 in Patients With Advanced Hepatocellular Carcinoma.

Advanced Hepatocellular Carcinoma With c-MET Dysregulation

China, Hong Kong, Thailand, Singapore
Janssen Research & Development, LLC

Completed

Efficacy and Safety of Combinations of AL-335, Odalasvir (ODV) and Simeprevir (SMV) in the Treatment of Chronic Hepatitis C Infection

Hepatitis C, Chronic

Poland, Belgium, Germany, Spain, Canada, Singapore
AbbVie

Completed

A Study to Evaluate the Efficacy and Safety of Glecaprevir/Pibrentasvir (ABT-493/ABT-530) in Treatment-Naive and Treatment-Experienced, Non-Cirrhotic Asian Adults With Chronic Hepatitis C Virus Genotype (GT) 1 to GT6 Infection With or Without Human Immunodeficiency Virus Co-Infection (VOYAGE-1)

Hepatitis C Virus (HCV)

China, Korea, Republic of, Singapore
Human Genome Sciences Inc.
Novartis

Completed

Efficacy of Albumin Interferon Alfa-2b With Ribavirin Compared to Peg-IFN Alfa-2a With Ribavirin in IFN Naive Patients Geno2/3

Chronic Hepatitis C

Korea, Republic of, United States, Spain, Canada, France, Australia, Israel, Singapore, Thailand, Malaysia, Sweden, Belgium, Germany, Taiwan, Poland, Argentina, India, Puerto Rico, Brazil, Mexico, United Kingdom
GlaxoSmithKline

Completed

Antifibrotic Activity Of GI262570 In Chronic Hepatitis C Subjects

Cirrhosis, Liver

United States, Taiwan, Germany, Israel, Australia, Singapore, Canada, Czechia, Korea, Republic of, Russian Federation, New Zealand, Romania, Puerto Rico, Malaysia
Bristol-Myers Squibb

Withdrawn

Safety and Efficacy Study of Pegylated Interferon Lambda Versus Pegylated Interferon Alfa, Plus Ribavirin in Subjects With Hepatitis C

Hepatitis C Virus (HCV)

India, Korea, Republic of, Poland, Taiwan, Spain, Canada, Russian Federation, Colombia, Singapore, Netherlands, Ireland, United Kingdom, Czech Republic, Hungary, Romania, Hong Kong, Turkey, United States, China, Egypt
ETOP IBCSG Partners Foundation
Roche Pharma AG

Active, not recruiting

ABC-lung: Atezolizumab, Bevacizumab and Chemotherapy in EGFR-mutant Non-small Cell Lung Carcinoma (ABC-lung)

EGFRmutant Stage IIIB/C or IV Non-squamous NSCLC

Singapore, Spain, Korea, Republic of, Switzerland, Germany
Bristol-Myers Squibb

Completed

Safety and Efficacy Study of Pegylated Interferon Lambda With and Without Daclatasvir, Compared to Pegylated Interferon Alfa, Plus Ribavirin in Subjects With Hepatitis C Genotype 2 and 3 (PRINCIPAL)

Hepatitis C Virus (HCV)

Australia, Belgium, France, Italy, Japan, Korea, Republic of, Mexico, Russian Federation, Taiwan, United States, Chile, Hong Kong, Argentina, Netherlands, United Kingdom, Singapore, New Zealand, Finland, Greece
Sun Pharma Advanced Research Company Limited

Active, not recruiting

Safety and Anti-leukemic Activity of Vodobatinib (K0706) for Treatment of Ph+ CML Resistant/Intolerant to ≥3 Prior CML Therapies

Healthy (For Part A) | Chronic Myeloid Leukemia (for Part B and C)

United States, Spain, Hungary, Italy, India, Belgium, France, Romania, Singapore, United Kingdom, Korea, Republic of, Turkey
Mandos LLC

Terminated

Adrabetadex to Treat Niemann-Pick Type C1 (NPC1) Disease

Niemann-Pick Disease, Type C

United States, Australia, United Kingdom, Turkey, Switzerland, Germany, New Zealand, Singapore, France
Mandos LLC

Completed

VTS-270 to Treat Niemann-Pick Type C1 (NPC1) Disease

Niemann-Pick Disease, Type C

United States, Australia, United Kingdom, Germany, France, New Zealand, Singapore, Spain, Turkey

Clinical Trials on C. Diff in Singapore

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Türkiye

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations